These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 1621244)

  • 21. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D; Lijnen HR; Vanlinthout I; Kieckens L; Nelles L; Stassen JM
    Thromb Haemost; 1991 Feb; 65(2):174-80. PubMed ID: 1905070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
    Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
    Thromb Haemost; 1992 Dec; 68(6):672-7. PubMed ID: 1287881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure and function of human tissue-type plasminogen activator (t-PA).
    van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H
    J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1990 Nov; 64(3):450-4. PubMed ID: 2096491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
    Collen D; Lijnen HR; Bulens F; Vandamme AM; Tulinsky A; Nelles L
    J Biol Chem; 1990 Jul; 265(21):12184-91. PubMed ID: 2115513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
    Gurewich V; Pannell R; Broeze RJ; Mao J
    J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
    Vaughan DE; Declerck PJ; Van Houtte E; De Mol M; Collen D
    Thromb Haemost; 1992 Jul; 68(1):60-3. PubMed ID: 1514173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of fibrin-mediated stimulation of plasminogen activation by tissue-type plasminogen activator (t-PA) and fibrin-dependent enhancement of amidolytic activity of t-PA.
    Fischer BE
    Blood Coagul Fibrinolysis; 1992 Apr; 3(2):197-204. PubMed ID: 1606292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
    Holvoet P; Laroche Y; Lijnen HR; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
    J Biol Chem; 1991 Oct; 266(29):19717-24. PubMed ID: 1918077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular biology of tissue-type plasminogen activator (t-PA) and clinical application of recombinant t-PA].
    Fukao H; Matsuo O
    Nihon Rinsho; 1993 Jun; 51(6):1620-6. PubMed ID: 8320841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
    Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
    Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen.
    Lijnen HR; Van Hoef B; Collen D
    Thromb Res Suppl; 1990; 10():45-54. PubMed ID: 2107598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.